Qin Siwen, Cao Jilong, Ma Xiaoxue
Department of Pediatrics, The Fourth Hospital of China Medical University, Shenyang, China.
Party Affairs and Administration Office, The Fourth Hospital of China Medical University, Shenyang, China.
Front Cell Dev Biol. 2023 Aug 21;11:1228624. doi: 10.3389/fcell.2023.1228624. eCollection 2023.
In recent years, immunotherapy has been increasingly used in clinical practice to treat tumors. However, immunotherapy's efficacy varies between tumor types and patient populations, and long-term drug resistance often occurs during treatment. Therefore, it is essential to explore the molecular mechanisms of immunotherapy to improve its efficacy. In this review, we focus on the significance of tumor-derived exosomes in the clinical treatment of tumors and how modifying these exosomes may enhance immune effectiveness. Specifically, we discuss exosome components, such as RNA, lipids, and proteins, and the role of membrane molecules on exosome surfaces. Additionally, we highlight the importance of engineered exosomes for tumor immunotherapy. Our goal is to propose new strategies to improve the efficacy of tumor immunotherapy.
近年来,免疫疗法在临床实践中越来越多地用于治疗肿瘤。然而,免疫疗法的疗效在不同肿瘤类型和患者群体之间存在差异,并且在治疗过程中经常会出现长期耐药性。因此,探索免疫疗法的分子机制以提高其疗效至关重要。在本综述中,我们重点关注肿瘤衍生外泌体在肿瘤临床治疗中的意义以及修饰这些外泌体如何增强免疫效果。具体而言,我们讨论外泌体的成分,如RNA、脂质和蛋白质,以及外泌体表面膜分子的作用。此外,我们强调工程化外泌体在肿瘤免疫治疗中的重要性。我们的目标是提出提高肿瘤免疫治疗疗效的新策略。